Gabapentin: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "* " to "*") |
(Text replacement - "w/o" to "with out") |
||
| Line 28: | Line 28: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Partial seizures=== | ===Partial seizures=== | ||
''Adjunct for partial seizures | ''Adjunct for partial seizures with out secondary generalization in patients> 12yo w/ epilepsy; also adjunctive therapy for partial seizures in patients 3-12 years'' | ||
*<3 years: Safety and efficacy not established | *<3 years: Safety and efficacy not established | ||
*3-12 years (initial dose): 10-15mg/kg/day PO divided q8hr initially; titrate up in 3d to effective maintenance dose | *3-12 years (initial dose): 10-15mg/kg/day PO divided q8hr initially; titrate up in 3d to effective maintenance dose | ||
Revision as of 06:22, 10 July 2016
General
- Type: Anticonvulsants; GABA analog
- Dosage Forms: capsule, tablet, oral solution 250mg/5mL
- Common Trade Names: Neurontin, Gralise
Adult Dosing
Partial Seizures
- Adjunctive therapy for partial seizures with or without secondary generalization
- Initial: 300 mg PO q8hr
- May increase up to 600 mg PO q8hr
Post herpetic neuralgia
- Day 1: 300 mg PO qDay
- Day 2: 300 mg PO q12hr
- Day 3: 300 mg PO q8hr
Muscle Cramps (Off-label)
- 100-300 mg PO qHS; may titrate to 300-400 mg q8hr PRN
Anxiety (Off-label)
- 300mg PO qHS initially, THEN 300 mg PO q8h; may further increase as tolerated
Diabetic Neuropthy (Off-label)
- 900 mg/day PO initially; may increase gradually q3Days to 1800-3600 mg/day
Neuropathic Pain
- 600 mg PO load in ED
- D/c with 300 mg --> 900 mg per day divided tid (as in post-herpetic neuralgia regimen)
- D/c with pain specialist follow-up
- Max dosage 3600 mg if patient already on gabapentin
- Taper dose > 7 days to discontinue[1]
Pediatric Dosing
Partial seizures
Adjunct for partial seizures with out secondary generalization in patients> 12yo w/ epilepsy; also adjunctive therapy for partial seizures in patients 3-12 years
- <3 years: Safety and efficacy not established
- 3-12 years (initial dose): 10-15mg/kg/day PO divided q8hr initially; titrate up in 3d to effective maintenance dose
- 3-4 years (maintenance): 40 mg/kg/day PO divided q8hr
- 5-12 years (maintenance): 25-35 mg/kg/day PO divided q8hr
- >12 years (initial dose): 300mg PO q8h; may increase up to 600 mg PO q8h
Special Populations
- Pregnancy Rating: C
- Lactation: Enters breast milk; use with caution
- Renal Dosing
- CrCl>60 mL/min: 300-1200 mg PO TID
- CrCl 30-60 mL/min: 200-700 mg q12hr
- CrCl 15-29 mL/min: 200-700 mg qDay
- CrCl<15 mL/min: 100-300 mg qDay
- HD: 125-350 mg posthemodialysis after each 4h dialysis interval
- Hepatic Dosing
- Adult: no modifications
- Pediatric: no modifications
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- none
Common
- >10% ataxia, dizziness, fatigue, somnolence
- 1-10% diplopia, nystagmus, tremor, amblyopia, back pain, constipation, depression, dry mouth, dysarthria, dyspepsia, increased appetitie, leukopenia, myalgia, nervousness, peripheral edema, pharyngitis, puritis, rhinitis, vasodilation, weight gain
Pharmacology
- Half-life: 5-7hr
- Metabolism: not metabolized
- Excretion: Renal
- Mechanism of Action: GABA analogue, but has no effect on GABA binding, uptake or degradation; mech for analgesic and anticonvulsant activity unknown
See Also
References
- ↑ Epocrates. Gabapentin Monograph. https://online.epocrates.com/u/10a1022
